Longevity UnmaskedLongevity Unmasked

Question 414 of 433

What is coming for Alzheimer’s disease?

Lab robot arm handling a sample plate under gold light

The short answer

Earlier detection by blood test, treatment at home, and, most important, trials testing whether treating people before symptoms can prevent the disease.

The blood tests and the home-injected antibody were described in Part 12. The pivotal studies are two large trials giving anti-amyloid drugs to people who have amyloid in the brain and no symptoms yet. Results are expected in 2027 and 2028. If they succeed, Alzheimer’s care would begin to resemble heart care: find the risk early and treat it before damage is done. If they fail, the field will have to look beyond amyloid.

Also in early development is a protein called klotho, which improved memory in aged monkeys. The first human study is planned for 2027.

“This book is for education. It is not medical advice, and reading it does not make you my patient or create a doctor-patient relationship.” From the book’s medical disclaimer. Full disclaimer

Evidence scope
ONGOING HUMAN RESEARCH — Presymptomatic Alzheimer’s intervention and novel targets; prevention efficacy unresolved.Evidence grade (draft mapping)Grade pendingPart 28, Q414 · Sources: R15

Sources cited

  • R15 Eisai. FDA Approves LEQEMBI IQLIK Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease. July 13, 2026. Link pending verification
All of Part 28

Related questions